Jill Abrams
Areas of Focus
Overview
Jill Abrams is a senior counsel in Crowell & Moring’s Washington, D.C. office and a member of the firm’s Health Care Practice. She advises on managed care compliance and enforcement matters, with a focus on Medicare Advantage (MA) and Medicare Part D. Prior to joining Crowell, she spent over 20 years at the U.S. Department of Health and Human Services (HHS), where she took a key role in most of the significant enforcement matters regarding these programs.
Career & Education
- University of Michigan Law School, J.D., 1999
- University of Pennsylvania, B.A., 1994
- District of Columbia
Jill 's Insights
Client Alert | 4 min read | 02.11.26
Consolidated Appropriations Act Introduces Sweeping Reforms for Pharmacy Benefit Managers
On February 3, 2026, President Trump signed a $1.2 trillion spending deal that, among other points, introduced significant regulatory changes for Medicare Part D plans and PBMs providing services to PDP sponsors in the Medicare Advantage and Medicare Part D programs, and imposed significant new restrictions and transparency requirements on PBMs contracting with private group health plans.
Client Alert | 2 min read | 02.03.26
Client Alert | 7 min read | 01.30.26
CMS Proposes CY 2027 Growth Rate and Changes to Risk Adjustment for Medicare Parts C and D
Client Alert | 10 min read | 12.24.25
Recognition
- Office of the General Counsel: Excellence of Service Group Award, Inflation Reduction Act Implementation and Legal Defense Team, 2024
- Centers for Medicare and Medicaid Services Division: Program Impact Award, Risk Adjustment Data Validation Final Rule Team, 2023
- Centers for Medicare and Medicaid Services Division: Secretary’s Award for Distinguished Service, Medicare Modernization Act Regulations Development Team, 2005
Jill 's Insights
Client Alert | 4 min read | 02.11.26
Consolidated Appropriations Act Introduces Sweeping Reforms for Pharmacy Benefit Managers
On February 3, 2026, President Trump signed a $1.2 trillion spending deal that, among other points, introduced significant regulatory changes for Medicare Part D plans and PBMs providing services to PDP sponsors in the Medicare Advantage and Medicare Part D programs, and imposed significant new restrictions and transparency requirements on PBMs contracting with private group health plans.
Client Alert | 2 min read | 02.03.26
Client Alert | 7 min read | 01.30.26
CMS Proposes CY 2027 Growth Rate and Changes to Risk Adjustment for Medicare Parts C and D
Client Alert | 10 min read | 12.24.25
Insights
Wilmer Rehires Trump Transition Attorney, Crowell Adds To Health Care Team
|09.29.25
The National Law Journal
Practices
Industries
Jill 's Insights
Client Alert | 4 min read | 02.11.26
Consolidated Appropriations Act Introduces Sweeping Reforms for Pharmacy Benefit Managers
On February 3, 2026, President Trump signed a $1.2 trillion spending deal that, among other points, introduced significant regulatory changes for Medicare Part D plans and PBMs providing services to PDP sponsors in the Medicare Advantage and Medicare Part D programs, and imposed significant new restrictions and transparency requirements on PBMs contracting with private group health plans.
Client Alert | 2 min read | 02.03.26
Client Alert | 7 min read | 01.30.26
CMS Proposes CY 2027 Growth Rate and Changes to Risk Adjustment for Medicare Parts C and D
Client Alert | 10 min read | 12.24.25
